Summit Lens

About Summit Lens

Healthcare is shaped by three forces: patients, policy, and products. Summit Lens explores what happens when science meets the real world — when a discovery becomes a drug, a drug meets the healthcare system, and new technologies change how medicine is developed and delivered. Each episode starts with one question and follows it through the system, so you come away understanding how healthcare works, why it matters, and what to watch next. Hosted by Shanyue.

Publisher

Eva

Category

science

Language

en

Explicit

No

First episode

25 Mar 2026

Latest episode

26 Oct 2026

Latest episodes

14 episodes in the feed.

1. 

   26 Oct 2026

   When Government Gets an AI Copilot

   AI is helping pharmaceutical companies develop drugs. Now, the FDA has an AI assistant to help review the evidence. But that's just the beginning. Across American healthcare, government agencies are increasingly using AI to review medical payments, document patient visits, and support biomedical research. So what happens when the institutions responsible for regulating, paying for, and delivering healthcare start using AI themselves? In this episode, we explore FDA's Elsa, Medicare's WISeR model, AI-assisted clinical documentation at the VA, and research initiatives from NIH and ARPA-H. Along the way, we examine the promises of greater efficiency and the harder questions about accuracy, financial incentives, human oversight, and accountability. Because making a process faster doesn't necessarily mean making it better. The question is: faster for whom, and what happens to the person waiting? Timestamps 00:00 When Government Gets an AI Copilot 02:09 FDA: AI at the Reviewer's Desk 05:44 CMS: When a Patient Is Waiting 09:43 Medicare WISeR: The Hidden Work Behind AI Efficiency 14:19 VA: AI in the Exam Room 17:04 NIH & ARPA-H: Building the Future of AI Research 19:47 Who Is Accountable When AI Gets It Wrong? 22:15 Back to the FDA Table

2. 

   27 Sept 2026

   Can AI Build a Drug?

   AI can predict protein structures, search enormous chemical spaces, identify drug targets, and help design new molecules. But building a molecule is only the beginning. In this episode, we follow one fictional cancer drug, SL-101, through the modern R&D pipeline—from target discovery and medicinal chemistry to Phase II, biomarker selection, clinical trials, and one of the hardest decisions in pharma: whether to keep spending. Along the way, we look at how companies such as Insilico Medicine, Recursion, Isomorphic Labs, Tempus, Schrödinger, and Unlearn are applying very different kinds of AI to very different problems. The deeper question is whether AI can help pharma make better bets: choosing the right target, the right molecule, the right patient, and knowing when a program is no longer worth funding. Timestamps 00:00 A Drug at a Crossroads 04:17 What Should We Drug? AI Target Discovery 13:16 What Molecule Should We Make? 20:50 When Biology Fights Back: Phase I vs. Phase II 30:00 Who Actually Responds? Biomarkers and Patient Selection 37:25 When Should We Stop Spending? The Value of Failing Early 42:04 Can AI Make Clinical Trials Better? 48:43 Who Owns the Value? Big Pharma vs. AI Biotech 53:02 A Sequence of Better Bets

3. 

   13 Sept 2026

   When AI Enters the Exam Room

   AI can already read scans, flag high-risk patients, guide ultrasound exams, and even make some autonomous diagnostic decisions. But that raises a more important question: does a better model actually lead to better care? In this episode, we follow what happens after the algorithm gives an answer. We look at why GPT-4 did not automatically make physicians better diagnosticians, how AI cut mammography reading workload by 44%, why some clinical alerts become noise while others speed up stroke treatment, and what happens when AI moves expertise closer to the patient. We also look at one of the rare randomized trials linking an AI alert to lower mortality—and why some of the fastest-moving healthcare AI may be doing something far less glamorous: writing the clinical note. The real story of medical AI may not be whether machines can outperform doctors. It may be whether healthcare systems know what to do with what the machines find. Timestamps 00:08 The rise of AI in medicine 05:33 When smart AI doesn’t automatically make a smarter team 09:14 When the workflow is designed around AI 13:31 When an alert becomes noise 19:25 When the signal reaches an outcome 22:33 Moving expertise closer to the patient 28:21 Why the “boring” AI may move faster 31:24 Who decides when AI is good enough for healthcare?

4. 

   7 Sept 2026

   When Healthcare Becomes an Investment Thesis

   You may know your doctor. But do you know who owns the business around your doctor? Private equity usually does not show up in healthcare with a Wall Street label. It shows up more quietly, in the local practice that keeps its old name, the specialist group inside a hospital, or the clinic that suddenly feels more optimized than before. The care may look familiar. The ownership may not be. In this episode, we follow how private equity became one of the most important and least visible ownership forces in the US healthcare. The story starts with the private equity model itself: raise capital, use leverage, buy a platform, add smaller practices, centralize operations, optimize revenue, and sell on a fund timeline. Then we ask why healthcare fit that model so well. The answer is uncomfortable: fragmented providers, opaque prices, third-party payment, complex billing, recurring demand, and physicians exhausted by the business side of medicine. We follow that playbook from physician practices to emergency staffing, outpatient specialties, nursing homes, and hospital real estate. This is not a simple story about private equity being good or bad. Some practices need capital. Some physicians sell for rational reasons. Some platforms bring better technology and cleaner operations. But when care becomes an investment asset, the logic around the exam room can change: what gets scheduled, what gets billed, which services grow, how doctors practice, and what patients experience without ever seeing the ownership change. The takeaway is simple: In the US healthcare, ownership is now part of the care model. The question is no longer only, “Who is my doctor?” It is also, “Who owns the system around my doctor and what is that owner optimized to do?” Timestamps 00:07 When Healthcare Becomes an Investment Thesis 04:03 How the Private Equity Model Works 08:46 Why Healthcare Fit the Financial Engine 10:29 The Roll-Up Playbook 16:38 Envision, Surprise Billing, and the No Surprises Act 26:43 Specialty Roll-Ups and Outpatient Care 32:36 When Financial Engineering Hits High-Risk Care 39:31 What Changes for Doctors, Patients, and Prices 43:19 How Regulators Are Pushing Back 47:15 Who Owns the System Around Your Doctor?

5. 

   30 Aug 2026

   Why Hospitals Became the Price Setters

   Why can the same care cost more when the doctor, the room, and the service have not changed? In this episode, we look at how hospitals became some of the most powerful price setters in American healthcare. We start with a routine cardiology visit that suddenly costs almost three times more after the practice becomes part of a hospital system. From there, we unpack the larger structure behind that bill: hospital consolidation, must-have health systems, commercial prices, facility fees, physician practice acquisitions, and the policy fight over site-neutral payments. This is not a simple story about hospitals being good or bad. Some health systems have enormous leverage. Some rural hospitals are barely staying open. And many policy solutions come with real tradeoffs. But the central tension is clear: in healthcare, scale can create survival — and scale can create pricing power. Timestamps 00:06 Why Hospitals Became the Price Setters 05:34 Hospitals as the Load-Bearing Wall of Healthcare Spending 12:10 Three Consolidation Playbooks 15:42 When the Bargaining Table Tips 19:07 Commercial Prices and the Cross-Subsidy Debate 25:21 Facility Fees and the Site-of-Care Economy 30:14 The Site-Neutrality Fight 33:06 Physician Practice Acquisition and Referral Control 34:27 The Anticompetitive Mechanisms Behind Doctor Buyouts 37:01 The Invisibility Problem in Healthcare Acquisitions 40:50 The Rural Hospital Tradeoff 45:15 Four Ways the System Pushes Back 52:37 Why Hospital Market Power Matters

6. 

   19 Aug 2026

   Why Having Insurance Still Feels Expensive

   What does it actually mean to have health insurance in America? In this episode, we look at the Affordable Care Act not as a partisan debate, but as a systems story. The ACA changed who could enter the insurance market. It made it harder for insurers to deny coverage because of pre-existing conditions, removed annual and lifetime limits, expanded Medicaid in many states, and created subsidized marketplaces for people outside employer coverage. But it did not fully change what care costs once someone gets inside the system. So the central question is not simply whether the ACA succeeded or failed. It is what kind of problem the law was built to solve, and what kind of problem it left behind. We follow that question from a kitchen table during open enrollment to pre-ACA medical underwriting, marketplace plan design, narrow networks, underinsurance, Medicaid expansion, temporary subsidies, and the deeper cost structure underneath American healthcare. Because having insurance is not always the same as being able to afford care. Timestamps 00:05 Why Having Insurance Still Feels Expensive 05:47 Before the ACA: The Exclusion Problem 13:36 How the ACA Rebuilt Insurance 22:41 When Coverage Is Hard to Use 33:16 Why Premiums and Deductibles Keep Rising 38:42 The Medicaid Expansion Divide 44:15 Temporary Subsidies and the 2026 Shock 48:39 What the ACA Solved and What It Didn’t 54:40 The Core Tradeoff and What Comes Next

7. 

   11 Aug 2026

   When Washington Becomes the Drug Price Negotiator

   What happens when Medicare stops only paying for drugs and starts naming the price? In this episode, we look at the Inflation Reduction Act and Medicare drug price negotiation, not as a policy explainer, but as a shift in power inside the U.S. drug market. For nearly two decades, Medicare Part D relied on private plans, PBMs, formularies, and rebates to negotiate drug costs. The IRA changed that architecture. Washington is now setting prices for selected high-spend Medicare drugs, and every part of the system is adapting around that new signal. We follow the story from the pharmacy counter to the manufacturer revenue model, the Part D plan bid, the PBM rebate negotiation, and the biotech investment decision. The question is no longer only whether Medicare can negotiate a lower price. It is what happens when that price becomes part of the operating system for the US drug markets. Timestamps 00:10 Drug Pricing and the IRA 05:15 Medicare’s Old Bargain 10:05 How Washington Names a Price 13:46 Which Drugs Got Picked and Why 27:54 The Hidden Half: Part D Redesign 37:33 Pharma’s Strategic Response 46:32 PBMs Adapt, Not Disappear 51:00 What Patients Actually Experience 56:55 The New Price Signal

8. 

   15 Jun 2026

   When GLP-1 Meets the Real World

   GLP-1 proved the science could work. The harder test began once patients tried to get it. In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy. The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive. And for many patients, the answer depends on which door is actually open. Timestamps 00:06  When the Prescription Isn’t Enough 07:47  How Compounding Became the Workaround 10:58  Why Coverage Still Creates Friction 16:17  Public Coverage and International Contrasts 21:53  PBMs, Employers, and the Formulary Fight 28:56  Cash Pay, TrumpRx, and New Access Lanes 35:19  The Pipeline Keeps Moving 35:48  Who Pays for Prevention?

9. 

   4 Jun 2026

   How GLP-1 Went From Biology to Blockbuster

   How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world? In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger. This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease. Timestamps 00:08 Intro: The 90-Second Hormone 02:23 The Gut’s Hidden Signal 05:01 The Discovery of GLP-1 10:32 The Gila Monster Breakthrough 16:04 Novo Solves the Delivery Problem 19:43 How GLP-1 Became a Platform 25:46 Beyond Diabetes 30:28 Lilly Raises the Benchmark 32:43 The Broader Implications of GLP-1 43:22 The future of GLP-1 49:14 When the Science Meets the System

10. 

    11 May 2026

    Why Making the Drug Is Only Half the Battle

    What does it actually take to turn a scientific breakthrough into a drug patients can access? In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure. This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time. Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value. Timestamps 00:00 Intro: The Drug Exists. Access Still Breaks Down 05:44 FDA Approval Is Not the Finish Line 09:41 Inside the R&D Risk Machine 13:24 Why Most Drug Trials Fail 15:32 The Patent Clock Starts Early 24:39 Why U.S. Drug Prices Run Higher 29:19 The Gross-to-Net Bubble 40:16 The Pharma Paradox 44:05 The IRA Changes the Game 50:59 Invention Is Not Enough

11. 

    27 Apr 2026

    Who Really Controls Your Prescription?

    If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay? In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access. I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine? From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient. Timestamps 00:00 — Cold open 03:23 — The pharmacy counter mystery 12:28 — Meet the PBM 16:35 — The evolution of PBMs 22:25 — How the machine works 38:01 — Why PBMs grew so powerful 49:33 — Critics vs. Defense 57:01 — What this means

12. 

    15 Apr 2026

    How Private Insurers Took Over American Healthcare

    What happens when an insurance company stops acting like a payer and starts acting like infrastructure? In this episode, I explore how private insurers became some of the most powerful actors in American healthcare. Using UnitedHealth Group as a central case study, I trace the shift from passive bill payer to managed care gatekeeper to vertically integrated healthcare empire. From Medicare Advantage and self-funded employer plans to Optum, PBMs, and the Change Healthcare crisis, this is a story about how private insurers scaled, consolidated, and embedded themselves into the plumbing of the U.S. health system. Timestamps 00:10 The role of health insurance in healthcare 07:02 The shift to managed care 11:00 Understanding UnitedHealth Group’s strategy 22:55 The impact of Medicare Advantage 33:25 Self-funded plans and pharmacy benefit managers 44:28 The vulnerability of consolidation 50:45 The corporate takeover of healthcare

13. 

    6 Apr 2026

    Why U.S. Healthcare Is So Complicated

    Why does getting care in America so often feel like navigating a maze? In this episode, I unpack the hidden architecture behind that confusion. U.S. healthcare is not one coherent system. It is a patchwork of rulebooks built over time through employer-sponsored insurance, Medicare, Medicaid, the ACA Marketplace, ERISA, and decades of political compromise. The result is a system where your job, age, income, disability status, or state can shape not just who pays, but which rules you live under. This episode explores why public programs increasingly flow through private managed care, why reform so often adds new layers instead of replacing old ones, and why complexity itself has become part of the business model of American healthcare. Timestamps 00:00 Why healthcare feels like a maze 07:48 How the patchwork was built 18:20 Five rulebooks, one system 33:10 Why reform adds more layers 46:37 The human cost of complexity 49:34 Three takeaways

14. 

    25 Mar 2026

    How America Built the World’s Most Expensive Healthcare System

    Why does the United States spend more on healthcare than any other country in the world, and still underperform on many basic health outcomes? In this episode, I unpack the machinery behind the high cost of American healthcare. From employer-sponsored insurance and tax policy to hospital consolidation, administrative complexity, and market power, this is a story about how the U.S. built a system that is extraordinarily expensive, highly fragmented, and remarkably hard to fix. This episode is not just about prices. It is about the architecture underneath them, the incentives, institutions, and historical decisions that made the system what it is today. Timestamps 00:00 The Start of a Healthcare Journey 01:45 Intro: Understanding the Cost of Healthcare 04:13 The Economics of Healthcare Spending 12:09 The Historical Context of Employer-Based Insurance 16:47 The Fragmentation of the Healthcare System] 23:27 Administrative Costs and Market Power 30:24 The Role of Pharmaceuticals in Healthcare Costs 35:36 Return on Investment in Healthcare 40:36 Conclusion

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

2 ratings

Spotify

5.0 / 5

1 ratings

Contact Summit Lens

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.